Abstract-Some beneficial effects of angiotensin-I-converting enzyme (ACE, kininase II) inhibitor therapy are attributed to enhancing the activity of bradykinin on its B 2 receptor. Independent of inhibition of bradykinin hydrolysis, ACE inhibitors enhance the action of bradykinin on its B 2 receptor by inducing crosstalk between ACE and the receptor. We investigated whether inhibitors of another kininase II-type enzyme, neprilysin (neutral endopeptidase 24.11; NEP), could augment bradykinin effects unrelated to blocking its breakdown using a NEP-resistant bradykinin analog as ligand. We used transfected Chinese hamster ovary (CHO) cells stably expressing human B 2 receptor and NEP (CHO/NEP-B 2 ) or only B 2 (CHO/B 2 ) as control and human pulmonary fibroblasts (IMR90), expressing B 2 , but more NEP than ACE. NEP inhibitor phosphoramidon (100 nmol/L), or omapatrilat, which inhibits both NEP and ACE, did not potentiate bradykinin in CHO/B 2 cells. In IMR90 cells, 10 nmol/L bradykinin elevated [Ca 2ϩ ] i and desensitized the receptor. Adding either 100 nmol/L omapatrilat or phosphoramidon resensitized the receptor to the ligand, which was abolished by receptor blocker HOE 140. Arachidonic acid release by bradykinin from CHO/NEP-B 2 cells was also augmented by 100 nmol/L phosphoramidon or omapatrilat about 3-fold, and again, the inhibitors resensitized the desensitized B 2 receptor. The inhibitors did not potentiate bradykinin when soluble rNEP was added to the medium of CHO/B 2 cells. Similar to ACE, NEP inhibitors potentiated bradykinin independent of inhibiting inactivation. Consequently, omapatrilat could augment bradykinin effects on B 2 , when either ACE or NEP is expressed close to receptor on cell membrane. Key Words: G proteins Ⅲ calcium Ⅲ arachidonic acids Ⅲ angiotensin-converting enzyme Ⅲ receptors, bradykinin Ⅲ fibroblasts W e wished to establish whether, besides angiotensin I converting enzyme (ACE), inhibitors of another kininase II-type enzyme, 1 neprilysin (neutral endopeptidase 24.11, CD10, NEP), can also augment the effects of bradykinin (BK) on its B 2 receptor. This was to be tested on cells where expression of NEP is much higher than that of ACE. Although both enzymes cleave BK at a Pro 7 -Phe 8 bond and are Zn metallopeptidases, 1,2 they differ from each other in many ways. NEP cleaves higher molecular weight peptide substrates than does ACE. NEP hydrolyzes BK with a larger turnover number, but the K m of the peptide is also higher; consequently, ACE in solution has a higher specificity constant (500 min
W e wished to establish whether, besides angiotensin I converting enzyme (ACE), inhibitors of another kininase II-type enzyme, 1 neprilysin (neutral endopeptidase 24.11, CD10, NEP), can also augment the effects of bradykinin (BK) on its B 2 receptor. This was to be tested on cells where expression of NEP is much higher than that of ACE. Although both enzymes cleave BK at a Pro 7 -Phe 8 bond and are Zn metallopeptidases, 1,2 they differ from each other in many ways. NEP cleaves higher molecular weight peptide substrates than does ACE. NEP hydrolyzes BK with a larger turnover number, but the K m of the peptide is also higher; consequently, ACE in solution has a higher specificity constant (500 min Ϫ1 mol/L Ϫ1 ) than that of NEP (40 min Ϫ1 mol/L Ϫ1 ). 2, 3 Both human enzymes are concentrated in proximal tubular cells 4 -6 and seminal plasma, 7 but endothelial cells are much richer in ACE, whereas fibroblasts express more NEP. 8, 9 ACE and NEP are ectoenzymes on plasma membranes, but ACE is type I, a transmembrane enzyme, 10 whereas NEP is type II. 11 The former is inserted into the membrane at its C-terminus, 10, 12 but, in the latter, the transmembrane anchor is at the N-terminus. 11 The distribution of ACE and NEP also differs in various species; for example, in rat heart 13 and urine 14 NEP is a major kininase.
In the present experiments, we used a BK analog (BKan) that activates the B 2 receptor, but is resistant to ACE and carboxypeptidase 15, 16 and, as shown below, to NEP. To study the crosstalk between the BK B 2 receptor and NEP, we transfected cells to express human NEP and B 2 receptor alone or together and used a human fibroblast cell line with native B 2 receptor but with much more NEP than ACE. Both specific ACE and NEP inhibitors (enalaprilat and phosphoramidon) and the dual inhibitor omapatrilat were tested.
Methods

Materials
Chinese hamster ovary (CHO)-K1 cells and human fetal lung fibroblast (IMR)-90 cells were from American Type Culture Collection (Rockville, Md). Purified human recombinant neprilysin (rNEP) and the cDNA of human neprilysin were gifts from Prof Philippe Crine (Université de Montreal). The cDNA of human ACE, the cDNA encoding the human BK B 2 receptor, and the neomycin resistant gene (pH␤Apr-3p-neo) were from Prof P. Corvol 
Human NEP Construct
Plasmid pRcCMV/NEP (provided by Prof Crine) was digested with EcoRI restriction enzyme to obtain the full-length NEP cDNA, which was ligated into the pcDNA6/V5-His expression vector and used for transfecting CHO/B 2 cells. 17 
Cell Culture
CHO cells were grown, subcultured, and transfected as described. 16, 17 Following transfection, cells were subjected to selection using Ham's F-12 medium, containing 10 g/mL blasticidin (pcDNA6 vector contains blasticidin resistance gene). After selection, clones were harvested and propagated using cloning rings. The clone with the highest NEP activity was chosen for continued culture. IMR-90 cells were grown in minimum essential Eagle's medium containing 10% fetal bovine serum. 
Measurement of [
Potentiation of BK, Desensitization and Resensitization of the Receptor
Monolayers of CHO/NEP-B 2 cells, loaded with [
3 H] AA, were exposed to 10 nmol/L BKan given alone, or together with the potentiating agent to be tested for 30 or 60 minutes. [ 3 H] AA released into the medium was determined.
In control experiments, omapatrilat or phosphoramidon was ineffective in cells that lacked NEP or in the absence of receptor agonist. To show the involvement of the B 2 BK receptor, its blocker HOE 140 (0.1 to 1.0 mol/L) was used routinely. After desensitization by initial exposure of cells to kinin, sensitivity to BKan (resensitization by NEP inhibitor) was measured either by [ 3 H] AA release or by elevation of [Ca 2ϩ ] i level. 16, 17 Enzyme Assay
Generally, the activity of NEP was determined from the percent inhibition with 1 mol/L phosphoramidon at pH 6.5 18 with GlutAla-Ala-Phe-methoxynaphthylamine (MNA) (Enzyme System Products) substrate. ACE activity was assayed with hippuryl-His-Leu at pH 8.0, 150 mmol/L NaCl, and with or without 1 mol/L enalaprilat as inhibitor. Crude cell homogenates were prepared by harvesting cells into ice-cold Tris-maleate pH 7.4 buffer and disrupted by a sonic dismembranator (Artek Corp); after, they were briefly centrifuged at 1,000g to remove intact cells and nuclei.
Results
Resistance of BKan to NEP Hydrolysis
The resistance of BKan to hydrolysis by ACE was reported. 16 Whether BKan could be cleaved by human rNEP was tested by comparing the hydrolysis of BK and BKan under similar conditions, followed by analysis of reaction products by HPLC using standards to identify and quantitate product peaks. The 
Suitability of IMR-90 Cells
IMR-90 cells are an established, well-characterized, and widely used cell line of normal human embryonic fibroblasts. They express the BK B 2 receptor. 19 To determine the ratio of NEP to ACE, we assayed NEP and ACE in IMR-90 cell lysates. IMR-90 cell lysates were incubated with Glut-AlaAla-Phe-MNA or hippuryl-His-Leu substrates. Cleavage, or inhibition by the specific inhibitors phosphoramidon or enalaprilat (1 mol/L), was taken as NEP and ACE activities in the cells. The actual amount of each enzyme in the lysate was calculated from the established kinetic parameters for these enzymes. 20 
Resensitization of Bradykinin B 2 Receptor by Omapatrilat
In experiments with transfected CHO cells expressing both ACE and B 2 receptor (CHO/AB), changes in [Ca 2ϩ ] i were measured using BK as agonist, and either phosphoramidon, enalaprilat, or omapatrilat to resensitize the receptor. The inhibitor was added to make the cell's B 2 receptor, desensitized by the agonist, respond a second time to BK in the medium. 16 
Resensitization of B 2 Receptor in IMR-90 Cells
Addition of 10 nmol/L BKan to IMR-90 cells increased [Ca 2ϩ ] i level within seconds. After desensitization of the B 2 receptor with the first dose of the agonist (a second dose of BKan had no effect), phosphoramidon (100 nmol/L; Figure  2A ) or omapatrilat (100 nmol/L; Figure 2B ) resensitized the receptor to BKan present in the medium. These results indicate that in IMR-90 cells, the NEP inhibitor and omapatrilat, the dual inhibitor, affected the B 2 receptor through NEP. The effect of enalaprilat activity was insignificant (100 nmol/L; Figure 2C ; nϭ4) in these cells with low expression of ACE. The dual enzyme inhibitor, omapatrilat, on the other hand, increased [Ca 2ϩ ] i 3.9Ϯ0.9-fold while phosphoramidon elevated it 1.8Ϯ0.1-fold when resensitizing B 2 receptor to its ligand. The addition of phosphoramidon or omapatrilat to the IMR-90 cells in the absence of the peptide agonist did not change the intracellular calcium level, although cells could still respond to added ligand (not shown). Just as proven with ACE inhibitors, 16, 17, 21 the NEP inhibitors in the absence of BK did not activate the receptor. Figure 3 shows that the addition of HOE 140 (100 nmol/L) to the cells after stimulation with BKan (10 nmol/L), but before addition of omapatrilat (100 nmol/L; nϭ5), blocked the resensitization of the receptor to the BKan present in the medium. Consequently, resensitization was due to the reactivation of the B 2 receptor. 22, 23 Resensitization of Receptor in CHO/NEP-B 2 Cells In other control experiments, soluble human rNEP (50 ng/mL) was added to the medium of CHO/B 2 cells. Under these conditions, when NEP was not expressed on the plasma membrane but instead dissolved in the medium, neither phosphoramidon nor omapatrilat resensitized the B 2 receptors to BKan (not shown; nϭ3).
Discussion
ACE (kininase II) inhibitors have been used to treat millions of patients worldwide. Their beneficial effects, 24, 25 however, cannot be explained only by blocking Ang II release or BK inactivation. ACE inhibitors indirectly enhance the effect of BK on its B 2 receptor by inducing a protein-protein interaction (ie, a crosstalk between the enzyme and the receptor). 16, 17, 22, 23 Experiments in support of this hypothesis were done on the guinea pig ileum 26 and atrial tissues, 27 hog coronary arteries, 28 and cultured cells that were transfected or constitutively expressed ACE and B 2 receptor by using BK and its partially or fully ACE-resistant analogs. 16, 17, 22, 23 This enhancement of the B 2 receptor activation leads to an increased release of arachidonic acid and IP 3 , and elevation of [Ca 2ϩ ] i level, which can lead to an augmented liberation of prostaglandins and NO. Besides potentiating BK effects, ACE inhibitors resensitize the receptor after it has been desensitized by an agonist. 16, 17, [21] [22] [23] ACE and B 2 receptors have to be sterically close to induce an interaction. 16 The enhanced activation of BK receptor initiates a signal transduction pathway that differs from the primary effect of BK. 22 As shown above, the inhibition of NEP also enhances the effect of BK and the NEP-resistant BKan on the B 2 receptor. This was investigated with CHO-AB cells transfected to express ACE and B 2 receptor 17 , and CHO-NEP/B 2 cells transfected to express NEP and B 2 . Specific inhibitors enalaprilat and phosphoramidon enhanced the effect of BK only in the cell line that expressed either ACE or NEP, whereas omapatrilat elevated the effect of BKan in both cell types; thus, omapatrilat acted on both ACE and NEP to potentiate BK and resensitize the receptor. In the IMR-90 cells that constitutively express NEP overwhelmingly more than ACE, enalaprilat potentiated BK much less than phosphoramidon or omapatrilat, or did not potentiate BK at all.
NEP inhibitors had no effect on the B 2 receptor in the absence of NEP on the cell membrane. Furthermore, instead of being expressed on the plasma membrane when soluble rNEP was added to the medium, BK was again not potentiated.
All of these results are taken as an indication that NEP inhibitors enhance the effect of BK on its receptor by a mechanism similar to that of ACE inhibitors. Depending on the cell type, activation of the B 2 receptor is followed by the release of important vasoactive mediators. 29 The experiments showed that omapatrilat potentiated BK in cells where enalaprilat did not. The mode of action of a single inhibitor of both ACE and NEP, resulting in an indirect activation of the B 2 receptor, could be responsible for additional beneficial therapeutic effects of vasopeptidase inhibitors such as omapatrilat. 30 
